Innovent Annouces Multiple Clinical Study Results of Mazdutide to be Presented at the EASD 2024
SAN FRANCISCO and SUZHOU, China, Sept. 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that multiple clinical study results of mazdutide (GLP-1R/GCGR dual agonist) will be presented at the European Association for...
Olympic Legend Stephanie Rice Joins Unichi as Global Ambassador for Teddi Lab Gummy
SYDNEY, Sept. 2, 2024 /PRNewswire/ -- Unichi, Australia's premium health supplement brand, is proud to announce Olympic swimming champion Stephanie Rice as the global brand ambassador for Teddi Lab Gummy. Stephanie Rice is a three-time Olympic gold medallist, five-time world record holder, recipient of the Medal of the Order of Australia, and an inductee into both the Sports Australia...
ThinkCyte Secures $32 million in Series C Funding to Drive Global Expansion of VisionSort™
TOKYO and REDWOOD CITY, Calif., Aug. 31, 2024 /PRNewswire/ -- ThinkCyte today announced the successful completion of its Series C funding round. Including the equity financing secured last November, the company raised an additional $15 million in the extension round, bringing the total to $32 million. The extension round was led by Japan Green Investment Corp. for Carbon...
LifeTech Scientific Corporation Announced 2024 Interim Results: International Business Increased by 30%, Net Profit Margin Attributable to Owners of the Company Reached 35.8%
SHENZHEN, China, Aug. 30, 2024 /PRNewswire/ -- LifeTech Scientific Corporation (the "Company" or "LifeTech", Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its subsidiaries (the "Group") announced the consolidated results for the six months ended 30 June 2024 (the "Reporting Period")....
Pierre Fabre Laboratories receives European Commission Approval for BRAFTOVI®(encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a...
European approval is based on results from the Phase II PHAROS trial, which showed a meaningful clinical benefit to BRAFV600E mutated advanced NSCLC patients with an objective response rate (ORR) of 75% in treatment-naïve patients and 46% in previously treated patients. The safety profile is consistent with that observed in the approved metastatic melanoma...
Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China
BEIJING and SHANGHAI and BOSTON, Aug. 30, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that it has granted the China rights (including mainland China, Hong Kong, Macau, and Taiwan) of KRAS G12C inhibitor glecirasib and SHP2 inhibitor JAB-3312 to Shanghai Allist Pharmaceuticals Co., Ltd (688578.SH). According to the terms of the...
Breaking News | Sanyou Bio Launches Comprehensive Monkeypox Product Line
SHANGHAI, Aug. 30, 2024 /PRNewswire/ -- On August 28, 2024, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. announced the launch of a comprehensive product line targeting monkeypox, which includes antigens, monoclonal antibodies, and overexpression cell lines. This product line features 65 items across three main categories: 26 natural epitope antigens, 28 high-affinity, high-specificity monoclonal antibodies and 11 overexpression cell lines. These products...
Guardant Health Japan receives regulatory approval of Guardant360® CDx liquid biopsy as companion diagnostic for amivantamab-vmjw to identify patients with inoperable or recurrent NSCLC harbouring EGFR exon 20 insertion...
Guardant360® CDx is the first blood-based companion diagnostic to be approved in Japan for the detection of EGFR exon 20 insertion mutations TOKYO, Aug. 30, 2024 /PRNewswire/ -- Guardant Health Japan Corp. (HQ: Minato-ku, Tokyo/ Representative Director: Mika Takaki), a leading precision oncology company, today announced that the Ministry of...
Remarkable Announcement on Significant Fluctuation of the UTime’s Share Price
SHENZHEN, China, Aug. 30, 2024 /PRNewswire/ -- Dear Investors, Analysts and Media: Recently, UTime Ltd ("UTime") has experienced a period of unusual share price volatility in the capital markets. As a responsible company, we understand the concerns of market participants about such situations and believe that it is necessary to provide the public with transparent and formalized information in...
Unlock the Full Potential of Cell and Gene Therapies: The 2024 GenScript Biotech Global Forum Heads to London
PISCATAWAY, N.J., Aug. 29, 2024 /PRNewswire/ -- The cell and gene therapy (CGT) industry has witnessed remarkable growth in recent years. According to an analysis by RSM US LLP, CGT therapies accounted for 10% of all FDA-approved drugs last year, with the number of approvals anticipated to continue rising. These therapies are demonstrating substantial application potential, establishing themselves as...
